

VGYAAN Pharmaceuticals Launches Clomipramine Hydrochloride Capsules, USP, the Generic Version of ANAFRANIL™

July 2, 2021

Skillman, NJ -- VGYAAN Pharmaceuticals LLC today announced that it has launched Clomipramine Hydrochloride Capsules, USP, the generic version of ANAFRANIL™.

VGYAAN's Clomipramine Hydrochloride Capsules are available in the following strengths and pack sizes:

- Clomipramine Hydrochloride Capsules, USP 25 mg, 90 count bottles
- Clomipramine Hydrochloride Capsules, USP 50 mg, 90 count bottles
- Clomipramine Hydrochloride Capsules, USP 75 mg, 90 count bottles

Clomipramine Hydrochloride is an antiobsessional drug that belongs to the class (dibenzazepine) of pharmacologic agents known as tricyclic antidepressants. It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

“We are very pleased to launch Clomipramine Hydrochloride Capsules, USP and add to our growing portfolio. We look forward to partnering with our customers across a wide range of channels,” said Nailesh Bhatt, Chief Executive Officer of VGYAAN Pharmaceuticals.

About VGYAAN Pharmaceuticals

VGYAAN Pharmaceuticals LLC, headquartered in Skillman, New Jersey is focused on developing and commercializing clinically critical drugs. VGYAAN is fully equipped and licensed to perform sales, marketing, and distribution of high quality and affordable drugs in the US with capabilities to serve clients across a wide range of channels. Our product portfolio includes solid orals and injectables in a broad range of therapeutic areas.

For more information, please visit www.vgyaan.com or contact media@vgyaan.com.

ANAFRANIL is a trademark of Mallinckrodt LLC.